Article
SLCs contribute to endocrine resistance in breast cancer: role of SLC7A5 (LAT1)
2019-02-21
Abstract excerpt
Resistance to endocrine therapies remains a major challenge for the successful management of patients with estrogen receptor-positive (ER+) breast cancers. Central to the development of resistance is the adaptive reprogramming of cellular metabolism in response to treatment. Solute carriers (SLCs) play a key role in metabolic reprogramming by transporting sugars, amino acids, and other nutrients and regulating the...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 437ef95f-9e95-52e7-90c7-239f7a19ff91
- DOI
- 10.1101/555342
